Omeros Stock Remains Higher On Promising Kidney Drug Trial Data
October 20, 2016 at 14:43 PM EDT
Cantor Fitzgerald analysts maintain their Buy rating on Omeros Corporation (NASDAQ: OMER) after promising OMS721 data in kidney ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.